The Most Important Articles of 2022 in Coronary disease

Discover the most important scientific articles of 2022on coronary disease in our website.

An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet therapy (DAPT) in 4579 patients treated with angioplasty and a biodegradable polymer sirolimus-eluting stent.

A Meta Analysis of Distal Transradial Access vs. Conventional Transradial

Transradial access is currently the preferred access for diagnostic and therapeutic interventions. However, about 7% of patients experience radial artery occlusion (RAO), which is not expressed by clinical symptoms. However, RAO is a limit for future interventions; it reduces the potential use of that artery as a conduit for aorto-coronary bypass and for the creation of arterio-venous fistula for hemodialysis.

Mortality and Bleeding in Access Site Choice: Systematic Review

In 1992, Kiemeneij performed the first transradial coronary procedure, following Campeau’s description of that access in 1989. It’s been 30 years since that milestone in interventional cardiology. Over time, the number of procedures conducted with this approach has increased exponentially, and it is the main approach in most centers in different clinical scenarios.

Are FFR and IVUS Similar to Assess Intermediate Lesions?

In coronary artery disease (CAD), lumen area and plaque burden, characteristics and physiological impact are what define prognosis. 

Is TCA Useful for Severe Impairment of Left Ventricular Ejection Fraction?

Heart disease is the most frequent cause of heart failure and, in some observational studies, transluminal coronary angioplasty (TCA) could help improve ventricular function.

DISCO RADIAL: Conventional or Distal Transradial Access?

Conventional transradial access (TRA) is already established as the access of choice for percutaneous coronary procedures, regardless of clinical presentation.

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12 months.

Is Epinephrine Superior to Adenosine in No-REFLOW?

In patients with acute coronary syndromeno-reflow prevalence is 32%. Different drugs—such as adenosine, verapamil, nitroprusside, or nicardipine— have been used for its intracoronary treatment, thus resulting in arterial hypotension.


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

More articles by this author

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...

SOLACI Technicians Webinar – Ultrasound Pulses + Calcium = Coronary Lithotripsy

The Latin American Society of Interventional Cardiology (SOLACI) invites you to participate in a new Live SOLACI Webinar specially designed for technicians, nurses, and...

COMPLICAT 2026: Collaborative learning to address complications in congenital and structural heart disease

Free online course in Spanish5 webinars in 2026 COMPLICAT 2026 returns with its second edition, consolidating itself as an innovative academic space dedicated to the...

CHIP LATAM | Chapter 2 – Mexico: Complications Workshop

The Latin American Society of Interventional Cardiology invites the entire medical community to participate in a virtual workshop on complications organized by SOLACI’s Complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...